Lumos Pharma, Inc. (NASDAQ:LUMO) Q2 2024 Earnings Call Transcript
Operator: Good afternoon and welcome to Lumos Pharma's Second Quarter 2024 Financial Results and Clinical Programs Update Call. Currently, all participants are in a listen-only mode.
No. | Hedge Fund | Shares | Value | Activity | % Port |
---|---|---|---|---|---|
1. | Renaissance Technologies Jim Simons | 215,814 | $500,688 | -2% | 0% |
2. | Leucadia National Ian Cumming And Joseph Steinberg | 120,651 | $279,910 | 0% | |
3. | Lion Point Didric Cederholm | 90,794 | $210,642 | 0.38% | |
4. | Millennium Management Israel Englander | 37,018 | $85,882 | -2% | 0% |
5. | Citadel Investment Group Ken Griffin | 18,745 | $43,488 | +42% | 0% |
No. | Name | Shares | Value | % Port |
---|---|---|---|---|
1. | 417,051 | $1,326,222 | 0% | |
2. | 406,611 | $1,293,023 | 0% | |
3. | 326,552 | $1,038,435 | 0% | |
4. | 244,082 | $776,181 | 0% | |
5. | 125,282 | $394,202 | 0.2% |